The acquisition is immediately transformative for Biogen's near-term growth, adding ~$689M in 2025 revenue from EMPAVELI/SYFOVRE and a nephrology pipeline. The $2B debt raise increases leverage but is manageable given Biogen's scale. Monitor Q2 earnings for updated 2026 guidance and SYFOVRE sales trajectory, which directly impacts CVR probability. The CVRs are non-transferable and not listed, so no direct trading vehicle exists.
Price Chart
Executive Summary
Biogen completed its $5.3B acquisition of Apellis Pharmaceuticals on May 14, 2026, adding commercial-stage products EMPAVELI and SYFOVRE. The deal was funded via a $2B term loan facility and cash. Apellis shareholders received $41/share plus one CVR per share, with potential milestone payments of up to $4/share tied to SYFOVRE net sales thresholds of $1.5B and $2.0B through 2031. The acquisition is expected to be accretive to Biogen's non-GAAP EPS in 2027.
Key Financial Metrics
Key Facts
- Biogen completed acquisition of Apellis Pharmaceuticals on May 14, 2026 for ~$5.3B in cash and CVRs.
- Apellis shareholders received $41.00 per share in cash plus one contingent value right (CVR) per share.
- CVRs entitle holders to up to $4.00 per share in milestone payments tied to SYFOVRE net sales thresholds of $1.5B and $2.0B through 2031.
- Biogen borrowed the full $2B under a new term loan facility ($1B 364-day Tranche A, $1B 2-year Tranche B) to fund the acquisition.
- The acquisition adds EMPAVELI and SYFOVRE, which recorded $689M in combined net product revenue in 2025.
- Biogen expects the deal to be accretive to non-GAAP diluted EPS in 2027 and to materially increase non-GAAP EPS CAGR through the end of the decade.
- Approximately 105.7M shares (82.4% of outstanding) were validly tendered in the offer.
- Biogen estimates it would need ~$582M to pay the maximum aggregate CVR milestone amounts if all thresholds are achieved.
Financial Impact
Total acquisition consideration ~$5.3B in cash plus up to ~$582M in potential CVR milestone payments. Funded via $2B term loan and cash on hand.
Risk Factors
- SYFOVRE faces competition from other GA therapies (e.g., Avacincaptad pegol) which could pressure market share and net sales.
- CVR milestones are contingent on SYFOVRE achieving $1.5B and $2.0B annual net sales by 2031—no guarantee of achievement.
- Integration risk: combining Apellis' commercial and R&D operations with Biogen's existing infrastructure.
- Increased leverage from $2B term loan; financial covenant requires max consolidated leverage ratio of 3.75x (4.25x temporarily post-acquisition).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222908 |
| Document: d109852dex101.htm | 0001193125-26-222908 |
| Document: d109852dex991.htm | 0001193125-26-222908 |
| Document: d109852d8k.htm | 0001193125-26-222908 |
| Document: 0001193125-26-222908-index-headers.html | 0001193125-26-222908 |
| Document: 0001193125-26-222908-index.html | 0001193125-26-222908 |
| Document: 0001193125-26-222908.txt | 0001193125-26-222908 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 28d ago | Press Release | $220.83 $217.36 | ▼ −1.57% | ▼ −0.36% | $219.88 (−0.43%) |
Sep 3, 2026 29d ago | Press Release | $224.51 $217.15 | ▼ −3.28% | ▼ −2.13% | $219.88 (−2.06%) |
Aug 6, 2026 8w ago | Press Release | $207.94 $209.83 | ▲ +0.91% | ▲ +0.51% | $219.88 (+5.74%) |
Jul 14, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Jun 17, 2026 15w ago | Press Release | $196.58 $201.96 | ▲ +2.74% | ▲ +4.40% | $219.88 (+11.85%) |
Jun 8, 2026 16w ago | ANALYST-UPGRADE | $192.62 $198.64 | ▲ +3.13% | ▲ +1.01% | $219.88 (+14.15%) |
Jun 4, 2026 17w ago | Press Release | $195.82 $199.96 | ▲ +2.12% | ▲ +4.67% | $219.88 (+12.29%) |
Jun 1, 2026 17w ago | Press Release | $192.22 $195.34 | ▲ +1.63% | ▲ +4.38% | $219.88 (+14.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access